29.64
-0.61(-2.02%)
Currency In USD
| Previous Close | 30.25 |
| Open | 29.96 |
| Day High | 29.96 |
| Day Low | 28.57 |
| 52-Week High | 53.27 |
| 52-Week Low | 19.45 |
| Volume | 598,921 |
| Average Volume | 717,206 |
| Market Cap | 1.93B |
| PE | -9.06 |
| EPS | -3.27 |
| Moving Average 50 Days | 29.2 |
| Moving Average 200 Days | 39.47 |
| Change | -0.61 |
If you invested $1000 in Kymera Therapeutics, Inc. (KYMR) since IPO date, it would be worth $891.16 as of June 01, 2025 at a share price of $29.64. Whereas If you bought $1000 worth of Kymera Therapeutics, Inc. (KYMR) shares 3 years ago, it would be worth $2,097.66 as of June 01, 2025 at a share price of $29.64.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Kymera Therapeutics to Announce KT-621 Phase 1 Healthy Volunteer Trial Results on June 2, 2025
GlobeNewswire Inc.
May 30, 2025 8:01 PM GMT
Company to host video webcast at 8:00 a.m. ET on Monday, June 2, 2025WATERTOWN, Mass., May 30, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecul
Kymera Therapeutics to Participate in Upcoming June Investor Conferences
GlobeNewswire Inc.
May 29, 2025 11:00 AM GMT
WATERTOWN, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that
Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International Conference
GlobeNewswire Inc.
May 19, 2025 4:15 PM GMT
KT-621, a potent, selective, oral STAT6 degrader, demonstrated comparable or superior activity to dupilumab in a newly disclosed preclinical chronic asthma model reversing disease progression KT-621 Phase 1 healthy volunteer SAD/MAD trial completed w